Evidence may support a greater comorbidity burden among patients with heart failure with preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF), although this finding was shown to be ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CLEVELAND -- Whether vagal nerve stimulation improved outcomes ...

prescription medicine Despite substantial advances in therapeutic options for HFrEF, significant gaps remain in the use of guideline-directed medical therapy in these patients. Heart failure affects ...

GLP-1s improved outcomes in patients with heart failure with preserved ejection fraction, with or without obesity, but those ...

Nine out of 10 hospitalized patients who have heart failure with reduced ejection fraction (HFrEF) may be potential candidates for the novel agent vericiguat (Merck Sharp & Dohme/Bayer) to lower their ...

Swedish investigators looked at potassium levels and all-cause mortality in HFrEF patients at 30 days, 12 months, and 5 years. Over all 3 time frames, the sweet spot in terms of lowest hazard risk for ...

“HFrEF drugs are also beneficial independent of one another, and 3 randomized trials suggest that higher doses are more effective than lower doses. Thus, in a large real-world cohort of HFrEF patients ...

Please provide your email address to receive an email when new articles are posted on . The benefits of empagliflozin compared with placebo for HF with reduced ejection fraction occurred regardless of ...

Start most patients newly diagnosed with heart failure with reduced ejection fraction on the disorder's four foundational drug regimens all at once, all on the day the diagnosis is made, Gregg C.

Recommendations that patients who have heart failure with reduced ejection fraction (HFrEF) receive so-called “quadruple” therapy are being hampered by drug pricing that can mean some Medicare ...

Heart failure is a common medical condition globally and in India. In India, about 1% to 1.5% of the adult population is estimated to have heart failure, with higher mortality rates than global ...

Treatment with the novel agent omecamtiv mecarbil did not improve exercise capacity in people with chronic heart failure with reduced ejection fraction (HFrEF), in the METEORIC-HF trial. The ...